Purpose: To assess hemoglobin (Hb) outcomes and fatigue-related quality-of-life (QoL)
(electronic assessment) in patients with solid tumors and symptomatic chemotherapy-induced
anemia receiving cytotoxic chemotherapy and darbepoetin alfa (DA) or another erythropoiesisstimulating agent according to European indication.